LTX-315通过诱导MyD88依赖的树突细胞成熟来触发抗癌免疫力
Xiao-Qing Li1,2, Takahiro Yamazaki3, Tianzhen He2
1Department of Biochemistry and Molecular Biology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin Medical University, Tianjin, China.
一种性的LTX-315通过激活托尔类受体7 (TLR7) 信号通路,有效地触发树突细胞 (DC) 成熟和抗黑色素瘤免疫力. 这一过程对于其抗癌免疫治疗潜力至关重要.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- LTX-315是一种合成的阴离子解质,具有已证明的抗癌活性和低毒性.
- 树突细胞 (DC) 成熟对于启动针对瘤的抗原特异性免疫反应至关重要.
- 了解LTX-315如何影响DC是其作为免疫治疗药物的发展的关键.
研究的目的:
- 研究LTX-315对瘤透树突细胞 (TiDC) 成熟的影响.
- 阐明LTX-315诱导DC成熟和抗黑色素瘤免疫的机制.
主要方法:
- 用LTX-315.5治疗实验性瘤模型.
- 对DC成熟标记和信号通路的分析.
- 对抗黑色素瘤免疫反应的评估.
- 调查MyD88在LTX-315中介作用中的作用.
主要成果:
- 治疗LTX-315诱导了TiDC成熟,无论是间接通过癌细胞衍生的警示蛋白,还是直接通过TLR7激活.
- 通过LTX-315直接激活TLR7,触发了细胞内信号通路 (NF-κB,MAPK,炎症体) 和1型干扰素的产生.
- LTX-315诱导的DC成熟和抗黑色素瘤免疫性取决于信号传感器MyD88.8.
结论:
- 通过间接和直接的TLR7介导机制,LTX-315有效地促进DC成熟.
- MyD88对LTX-315产生抗黑色素瘤免疫的能力至关重要.
- 这些发现强调了LTX-315作为抗癌免疫治疗剂的潜力.
更多相关视频
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
11:48Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
Published on: May 31, 2018
相关概念视频
Tumor Immunotherapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
